Analyzing Tilray Brands (NASDAQ:TLRY) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Tilray Brands (NASDAQ:TLRY) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Risk & Volatility

Tilray Brands has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Insider and Institutional Ownership

9.4% of Tilray Brands shares are owned by institutional investors. 1.6% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Tilray Brands and Recordati Industria Chimica E Farmaceutica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-16.91%	-10.39%	-7.38%
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%

Valuation & Earnings

This table compares Tilray Brands and Recordati Industria Chimica E Farmaceutica”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48 million	2.13	-$121.40 million	($1.40)	-2.17
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.10	$501.92 million	$2.80	21.00

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Tilray Brands and Recordati Industria Chimica E Farmaceutica, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	3	1	2.38
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00

Tilray Brands currently has a consensus target price of $5.90, suggesting a potential upside of 94.08%. Given Tilray Brands’ higher possible upside, equities research analysts clearly believe Tilray Brands is more favorable than Recordati Industria Chimica E Farmaceutica.

Summary

Recordati Industria Chimica E Farmaceutica beats Tilray Brands on 9 of the 14 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.